Agilent Technologies’ (A) Buy Rating Reaffirmed at The Goldman Sachs Group

Agilent Technologies (NYSE:AGet Rating)‘s stock had its “buy” rating reissued by research analysts at The Goldman Sachs Group in a research note issued to investors on Thursday. They presently have a $170.00 price target on the medical research company’s stock. The Goldman Sachs Group’s target price would suggest a potential upside of 41.22% from the company’s current price.

Other research analysts have also recently issued research reports about the company. Bank of America lowered their target price on Agilent Technologies from $179.00 to $160.00 and set a “buy” rating for the company in a research note on Wednesday, February 23rd. Truist Financial cut Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, April 19th. SVB Leerink cut their price objective on Agilent Technologies from $175.00 to $145.00 and set an “outperform” rating for the company in a report on Wednesday, February 23rd. Citigroup cut their price objective on Agilent Technologies from $190.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, February 23rd. Finally, StockNews.com upgraded Agilent Technologies from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 19th. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $163.62.

Shares of Agilent Technologies stock opened at $120.38 on Thursday. The business’s 50-day moving average price is $126.88 and its 200-day moving average price is $139.14. The company has a current ratio of 2.19, a quick ratio of 1.64 and a debt-to-equity ratio of 0.53. Agilent Technologies has a 12 month low of $112.64 and a 12 month high of $179.57. The firm has a market capitalization of $36.16 billion, a PE ratio of 30.55, a price-to-earnings-growth ratio of 2.80 and a beta of 1.06.

Agilent Technologies (NYSE:AGet Rating) last posted its quarterly earnings results on Tuesday, May 24th. The medical research company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.01. Agilent Technologies had a return on equity of 27.04% and a net margin of 18.70%. The business had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.62 billion. During the same period last year, the company earned $0.97 EPS. Agilent Technologies’s revenue for the quarter was up 5.4% compared to the same quarter last year. As a group, analysts predict that Agilent Technologies will post 4.86 earnings per share for the current fiscal year.

In other news, SVP Michael Tang sold 1,210 shares of the firm’s stock in a transaction that occurred on Friday, March 18th. The shares were sold at an average price of $136.21, for a total transaction of $164,814.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Large investors have recently made changes to their positions in the company. Associated Banc Corp lifted its stake in shares of Agilent Technologies by 2.9% during the fourth quarter. Associated Banc Corp now owns 2,554 shares of the medical research company’s stock valued at $408,000 after buying an additional 72 shares during the period. Glassman Wealth Services grew its holdings in Agilent Technologies by 47.4% during the 4th quarter. Glassman Wealth Services now owns 230 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 74 shares in the last quarter. Webster Bank N. A. grew its holdings in Agilent Technologies by 5.3% during the 4th quarter. Webster Bank N. A. now owns 1,606 shares of the medical research company’s stock worth $256,000 after acquiring an additional 81 shares in the last quarter. Franklin Street Advisors Inc. NC grew its holdings in Agilent Technologies by 3.9% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 2,151 shares of the medical research company’s stock worth $343,000 after acquiring an additional 81 shares in the last quarter. Finally, CENTRAL TRUST Co lifted its position in shares of Agilent Technologies by 4.0% in the 4th quarter. CENTRAL TRUST Co now owns 2,111 shares of the medical research company’s stock worth $337,000 after buying an additional 82 shares during the last quarter.

Agilent Technologies Company Profile (Get Rating)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.

Recommended Stories

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.